CSL has said that with flu jab rates in the US down between 12% and 14% this year, it has decided to delay the planned spinout of its Seqirus vaccines business and cut its profit forecast for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback